Loading patent…
AssigneeJuno Therapeutics, Inc.
InventorsSusan BYRNE, Richard SULLIVAN, Francois VIGNEAULT
Estimating the term…
Provided are CCT5-binding molecules, including anti-CCT5 antibodies and antigen- binding fragments thereof such as heavy chain variable (VH) regions and single-chain antibody fragments, and conjugates comprising the anti-CCT5 binding molecules such as immunoconjugates and antibody-drug conjugates, and chimeric receptors comprising the anti-CCT5 binding molecules such as chimeric antigen receptors (CARs). In some embodiments, the anti-CCT5 antibodies or antigen-binding fragments thereof specifically bind to CCT5. Also provided are genetically engineered cells expressing the CARs or CCT5-binding molecules and uses thereof such as in adoptive cell therapy.
An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment specifically binds to a peptide comprising an amino acid sequence set forth in SEQ ID NO:68 (X1SVEX5X6KX8), wherein X is any amino acid.
An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment specifically binds to an epitope that is or is contained within the peptide sequence set forth in SEQ ID NO:68 (X1SVEX5X6KX8), wherein X is any amino acid.
An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises:
An antibody or antigen-binding fragment thereof comprising:
An antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment comprises:
A single chain cell-surface protein, comprising an antibody or antigen-binding fragment that specifically binds to CCT5, and optionally a transmembrane domain.
A conjugate, comprising an antibody or antigen-binding fragment that specifically binds to CCT5 and a heterologous molecule or moiety.
A chimeric antigen receptor (CAR) comprising an extracellular portion comprising an antibody or antigen-binding fragment that specifically binds CCT5, a transmembrane domain and an intracellular signaling region.
A method of treatment, the method comprising administering to a subject a binding molecule comprising an antibody or antigen-binding fragment that specifically binds CCT5 for treating a disease or disorder.
Dependencies are inferred from the claim text.